FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012582893> ?p ?o ?g. }

• W3012582893 abstract "Abstract Background Plasmodium falciparum malaria is a public health problem worldwide. Malaria treatment policy has faced periodic changes due to emergence of drug resistant parasites. In Sudan chloroquine has been replaced by artesunate and sulfadoxine/pyrimethamine (AS/SP) in 2005 and to artemether–lumefantrine (AL) in 2017, due to the development of drug resistance. Different molecular markers have been used to monitor the status of drug resistant P. falciparum . This study aimed to determine the frequency of malaria drug resistance molecular markers in Southeast Sudan. Methods The samples of this study were day zero dried blood spot samples collected from efficacy studies in the Blue Nile State from November 2015 to January 2016. A total of 130 samples were amplified and sequenced using illumina Miseq platform. The molecular markers included were Pfcrt , Pfmdr1 , Pfdhfr , Pfdhps , Pfk13 , exonuclease and artemisinin resistant (ART‐R) genetic background ( Pfmdr2 , ferroredoxine , Pfcrt and Pfarps 10). Results Resistance markers for chloroquine were detected in 25.8% of the samples as mutant haplotype Pfcrt 72-76 CVIET and 21.7% Pfmdr1 86Y. Pfdhfr mutations were detected in codons 51, 59 and 108. The I C N I double-mutant haplotype was the most prevalent (69%). Pfdhps mutations were detected in codons 436, 437, 540, 581 and 613. The S GEG A triple-mutant haplotype was the most prevalent (43%). In Pfdhfr / Pfdhps combined mutation, quintuple mutation I C N I/S GEG A is the most frequent one (29%). Six of the seven treatment failure samples had quintuple mutation and the seventh was quadruple. This was significantly higher from the adequately responsive group (P < 0.01). Pfk13 novel mutations were found in 7 (8.8%) samples, which were not linked to artemisinin resistance. Mutations in ART‐R genetic background genes ranged from zero to 7%. Exonuclease mutation was not detected. Conclusion In this study, moderate resistance to chloroquine and high resistance to SP was observed. Novel mutations of Pfk13 gene not linked to treatment failure were described. There was no resistance to piperaquine the partner drug of dihydroartemisinin/piperaquine (DHA-PPQ)." @default.
• W3012582893 created "2020-03-27" @default.
• W3012582893 creator A5012253545 @default.
• W3012582893 creator A5015783215 @default.
• W3012582893 creator A5020422048 @default.
• W3012582893 creator A5051598312 @default.
• W3012582893 creator A5056359530 @default.
• W3012582893 creator A5073731898 @default.
• W3012582893 creator A5086197448 @default.
• W3012582893 creator A5087479596 @default.
• W3012582893 creator A5088958746 @default.
• W3012582893 date "2020-02-18" @default.
• W3012582893 modified "2023-10-16" @default.
• W3012582893 title "Assessment of Plasmodium falciparum drug resistance molecular markers from the Blue Nile State, Southeast Sudan" @default.
• W3012582893 cites W1745572029 @default.
• W3012582893 cites W1816616281 @default.
• W3012582893 cites W1940072256 @default.
• W3012582893 cites W1966124517 @default.
• W3012582893 cites W1969571661 @default.
• W3012582893 cites W1972177048 @default.
• W3012582893 cites W2000312835 @default.
• W3012582893 cites W2009021681 @default.
• W3012582893 cites W2019358007 @default.
• W3012582893 cites W2049209443 @default.
• W3012582893 cites W2053908340 @default.
• W3012582893 cites W2066014119 @default.
• W3012582893 cites W2101114302 @default.
• W3012582893 cites W2103439634 @default.
• W3012582893 cites W2119156545 @default.
• W3012582893 cites W2120009689 @default.
• W3012582893 cites W2124634096 @default.
• W3012582893 cites W2127733438 @default.
• W3012582893 cites W2131233198 @default.
• W3012582893 cites W2132730360 @default.
• W3012582893 cites W2132923209 @default.
• W3012582893 cites W2141125668 @default.
• W3012582893 cites W2145130342 @default.
• W3012582893 cites W2147148763 @default.
• W3012582893 cites W2162629756 @default.
• W3012582893 cites W2164272027 @default.
• W3012582893 cites W2170300319 @default.
• W3012582893 cites W2397788564 @default.
• W3012582893 cites W2398110767 @default.
• W3012582893 cites W2423770317 @default.
• W3012582893 cites W2547042202 @default.
• W3012582893 cites W2581965723 @default.
• W3012582893 cites W2590767446 @default.
• W3012582893 cites W2607254151 @default.
• W3012582893 cites W2737092650 @default.
• W3012582893 cites W2760888089 @default.
• W3012582893 cites W2771554855 @default.
• W3012582893 cites W2788823890 @default.
• W3012582893 cites W2791105224 @default.
• W3012582893 cites W2942729852 @default.
• W3012582893 cites W2951816935 @default.
• W3012582893 cites W2966014566 @default.
• W3012582893 cites W3130499523 @default.
• W3012582893 doi "https://doi.org/10.1186/s12936-020-03165-0" @default.
• W3012582893 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7029593" @default.
• W3012582893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32070355" @default.
• W3012582893 hasPublicationYear "2020" @default.
• W3012582893 type Work @default.
• W3012582893 sameAs 3012582893 @default.
• W3012582893 citedByCount "4" @default.
• W3012582893 countsByYear W30125828932020 @default.
• W3012582893 countsByYear W30125828932021 @default.
• W3012582893 countsByYear W30125828932022 @default.
• W3012582893 countsByYear W30125828932023 @default.
• W3012582893 crossrefType "journal-article" @default.
• W3012582893 hasAuthorship W3012582893A5012253545 @default.
• W3012582893 hasAuthorship W3012582893A5015783215 @default.
• W3012582893 hasAuthorship W3012582893A5020422048 @default.
• W3012582893 hasAuthorship W3012582893A5051598312 @default.
• W3012582893 hasAuthorship W3012582893A5056359530 @default.
• W3012582893 hasAuthorship W3012582893A5073731898 @default.
• W3012582893 hasAuthorship W3012582893A5086197448 @default.
• W3012582893 hasAuthorship W3012582893A5087479596 @default.
• W3012582893 hasAuthorship W3012582893A5088958746 @default.
• W3012582893 hasBestOaLocation W30125828931 @default.
• W3012582893 hasConcept C104317684 @default.
• W3012582893 hasConcept C114851261 @default.
• W3012582893 hasConcept C135763542 @default.
• W3012582893 hasConcept C159047783 @default.
• W3012582893 hasConcept C197754878 @default.
• W3012582893 hasConcept C203014093 @default.
• W3012582893 hasConcept C2776120307 @default.
• W3012582893 hasConcept C2777035104 @default.
• W3012582893 hasConcept C2777234095 @default.
• W3012582893 hasConcept C2777425658 @default.
• W3012582893 hasConcept C2778048844 @default.
• W3012582893 hasConcept C2778118209 @default.
• W3012582893 hasConcept C2778371730 @default.
• W3012582893 hasConcept C2780780316 @default.
• W3012582893 hasConcept C54355233 @default.
• W3012582893 hasConcept C86803240 @default.
• W3012582893 hasConceptScore W3012582893C104317684 @default.
• W3012582893 hasConceptScore W3012582893C114851261 @default.
• W3012582893 hasConceptScore W3012582893C135763542 @default.
• W3012582893 hasConceptScore W3012582893C159047783 @default.
• W3012582893 hasConceptScore W3012582893C197754878 @default.

• next